In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ...

This milestone makes Amvuttra the first medication in the US approved for both ATTR-CM and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN), positioning Alnylam as a direct ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well as royalties in the low double digits on sales of acoramidis in Japan, with ...

Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shot up 8.9% during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $44.00 to $50.00. JPMorgan ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic ...